Desh Rakshak

What does Desh Rakshak do?

Desh Rakshak Aushdhalaya Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology sector, focusing on Ayurvedic and herbal products. As of March 2025, it reported net sales of 4 Cr and a market cap of Rs 17 Cr.

Overview:<BR>Desh Rakshak Aushdhalaya Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacture of pure Ayurvedic and herbal products.<BR><BR>History:<BR>The company was originally established in 1901 as a proprietorship by Shri Bhagwant Rai Jain and was converted into a Private Limited Company in July 1994. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 17 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 17.00 <BR>Industry P/E: 27 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.34 <BR>Return on Equity: 5.37% <BR>Price to Book: 1.78 <BR><BR>Contact Details:<BR>Address: Bhagwant Kuti, Kankhal Haridwar UTT : 249408 <BR>Phone: 91-1334-243833 <BR>Email: daral96@yahoo.in/dral95@yahoo.com <BR>Website: http://www.deshrakshak.com

Has Desh Rakshak declared dividend?

No Dividend History Available

What is the technical trend for Desh Rakshak?

As of May 29, 2025, Desh Rakshak's technical trend is mildly bullish, supported by bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

As of 29 May 2025, the technical trend for Desh Rakshak has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some weakness in the short term. Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, supporting the overall mildly bullish trend. Daily moving averages are bullish, reinforcing the positive outlook. The KST indicates a mildly bearish trend on the weekly, but bullish on the monthly, which adds mixed signals. Dow Theory shows a mildly bearish trend on the weekly, with no trend on the monthly. Overall, the technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

Who are the peers of the Desh Rakshak?

Peers of Desh Rakshak include Genesis IBRC, Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, Chemo Pharma Lab, and Parmax Pharma. Desh Rakshak has the highest 1-year return at 415.29%, while most peers exhibit Below Average management risk and growth, with Vineet Laborator showing the lowest return at -49.62%.

Peers: The peers of Desh Rakshak are Genesis IBRC, Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, Chemo Pharma Lab, and Parmax Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at none, while Average management risk is found at Vineet Laborator, and the rest have Below Average management risk. Growth is Below Average for Vineet Laborator, Ishita Drugs, Phaarmasia, Zenith Health, Colinz Labs, Checkpoint Trend, and Parmax Pharma, while Desh Rakshak also falls into the Below Average category. Capital Structure shows Good ratings at Ishita Drugs, Zenith Health, and Colinz Labs, while the rest, including Desh Rakshak, have Below Average ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 415.29%, while the lowest is Vineet Laborator at -49.62%, indicating that Desh Rakshak significantly outperforms its peers. Additionally, Phaarmasia, Zenith Health, Colinz Labs, and Parmax Pharma all have negative six-month returns.

Who are in the management team of Desh Rakshak?

As of March 2022, the management team of Desh Rakshak includes Tosh Kumar Jain (Chairman & Managing Director), Monika Jain and Arihant Kumar Jain (Whole-time Directors), Mohit Kumar (Independent Director), Sohini Bansal (Company Secretary & Compliance Officer), and Shruti Gupta (Additional Director). Each member contributes to the company's governance and operations.

As of March 2022, the management team of Desh Rakshak includes the following individuals:<BR><BR>1. Tosh Kumar Jain - Chairman & Managing Director<BR>2. Monika Jain - Whole-time Director<BR>3. Arihant Kumar Jain - Whole-time Director<BR>4. Mohit Kumar - Independent Director<BR>5. Sohini Bansal - Company Secretary & Compliance Officer<BR>6. Shruti Gupta - Additional Director<BR><BR>Each member plays a crucial role in the governance and operational management of the company.

Who are the top shareholders of the Desh Rakshak?

The top shareholders of Desh Rakshak include promoters, with Tosh Kumar Jain holding 28.2% of the shares, and individual investors owning 35.58%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Desh Rakshak primarily include the promoters, with Tosh Kumar Jain holding the highest stake at 28.2%. Additionally, individual investors collectively own 35.58% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company, and there are no pledged promoter holdings.

How big is Desh Rakshak?

As of 24th July, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 31.00 Cr, with recent Net Sales of 8.54 Cr and a Net Profit of 0.72 Cr. The company's Shareholder's Funds are 9.48 Cr and Total Assets amount to 16.32 Cr.

As of 24th July, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 31.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 8.54 Cr and a Net Profit of 0.72 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 9.48 Cr and Total Assets of 16.32 Cr.

How has been the historical performance of Desh Rakshak?

Desh Rakshak's historical performance shows a mixed trend, with net sales increasing slightly to 6.27 Cr in Mar'25, stable operating profit, and improved profits before and after tax. Despite rising total liabilities, the company has demonstrated resilience with gradual improvements in profitability and sales.

Answer:<BR>The historical performance of Desh Rakshak shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Desh Rakshak's net sales have shown a slight increase from 6.01 Cr in Mar'24 to 6.27 Cr in Mar'25, following a peak of 6.60 Cr in Mar'21. The total operating income also reflects this trend, reaching 6.27 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 4.73 Cr in Mar'24 to 5.02 Cr in Mar'25. Operating profit (PBDIT) has remained relatively stable, with a slight decrease from 1.30 Cr in Mar'24 to 1.28 Cr in Mar'25. Profit before tax improved from 0.51 Cr in Mar'24 to 0.56 Cr in Mar'25, while profit after tax rose from 0.43 Cr to 0.48 Cr in the same period. The earnings per share (EPS) increased from 0.97 in Mar'24 to 1.08 in Mar'25. On the balance sheet, total liabilities increased from 15.74 Cr in Mar'23 to 16.32 Cr in Mar'24, with total assets also rising to 16.32 Cr. The cash flow from operating activities showed a positive change, with 1.00 Cr reported in Mar'24, while cash flow from investing activities remained negative at -1.00 Cr in Mar'22 and Mar'21. Overall, Desh Rakshak has demonstrated resilience in its financial performance, with gradual improvements in profitability and sales despite fluctuations in expenses and liabilities.

Is Desh Rakshak overvalued or undervalued?

As of November 21, 2025, Desh Rakshak is fairly valued with a PE ratio of 37.17 and an EV to EBITDA of 14.92, showing strong performance compared to peers like Sun Pharma and Cipla, despite recent stock volatility and a YTD return of 159.81%.

As of 21 November 2025, Desh Rakshak's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 37.17, an EV to EBITDA of 14.92, and a Price to Book Value of 1.90. In comparison to its peers, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla stands out as attractive with a PE ratio of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Despite the recent volatility in its stock price, which has seen a significant YTD return of 159.81% compared to the Sensex's 9.08%, the company's valuation metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. Overall, Desh Rakshak appears to be fairly valued in the current market environment.

When is the next results date for Desh Rakshak Aushdhalaya Ltd?

The next results date for Desh Rakshak Aushdhalaya Ltd is 13 February 2026.

The next results date for Desh Rakshak Aushdhalaya Ltd is scheduled for 13 February 2026.

Are Desh Rakshak Aushdhalaya Ltd latest results good or bad?

Desh Rakshak Aushdhalaya Ltd's latest results are poor, showing a 25.53% year-on-year decline in net sales and a 25% drop in net profit, despite a slight improvement in operating margins. The stock has also significantly decreased, trading down 71.72% from its 52-week high, indicating ongoing operational challenges.

Desh Rakshak Aushdhalaya Ltd's latest results indicate a challenging situation for the company. In Q3 FY26, the company reported net sales of ₹1.40 crores, which, while showing a sequential growth of 47.37% from the previous quarter, reflects a significant year-on-year decline of 25.53% compared to ₹1.88 crores in Q3 FY25. This pattern of revenue volatility raises concerns about the stability of demand and operational execution.<BR><BR>Net profit for the quarter was ₹0.09 crores, flat compared to the previous quarter but down 25% year-on-year. The operating margin improved to 17.86% from 15.43% a year ago, but this is a decline from 27.37% in the previous quarter, highlighting ongoing operational challenges.<BR><BR>Overall, the company's financial performance is characterized by declining revenues and profits, despite some improvements in margins. The stock has also faced significant pressure, trading down 71.72% from its 52-week high. Given these factors, the latest results can be considered poor, reflecting persistent operational headwinds and a lack of consistent growth.

Should I buy, sell or hold Desh Rakshak Aushdhalaya Ltd?

Why is Desh Rakshak Aushdhalaya Ltd falling/rising?

As of 18-Apr, Desh Rakshak Aushdhalaya Ltd's stock price is Rs 24.55, unchanged from the previous session, and has declined -9.07% over the last two days. The stock has underperformed its sector and the benchmark Sensex significantly, with a year-to-date decrease of -23.28% and weak long-term fundamentals contributing to a bearish outlook.

As of 18-Apr, Desh Rakshak Aushdhalaya Ltd's stock price is currently at Rs 24.55, showing no change from the previous trading session. The stock has been experiencing a downward trend, having fallen consecutively for the last two days with a total decline of -9.07% during this period. Today, it opened with a loss of -4.66% and reached an intraday low of Rs 24.55, indicating a lack of upward movement throughout the trading day.<BR><BR>In terms of performance, the stock has underperformed its sector by -4.95% today and has shown a significant decline of -8.05% over the past month, while the benchmark Sensex has increased by +3.18% during the same timeframe. Year-to-date, the stock has decreased by -23.28%, contrasting sharply with the Sensex's decline of only -7.89%. Over the past year, Desh Rakshak Aushdhalaya Ltd has generated a return of -13.62%, while the broader market has seen minimal change at -0.08%.<BR><BR>The stock is trading below its moving averages across various timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. Additionally, the company has shown weak long-term fundamental strength, with a low Return on Capital Employed (ROCE) of 6.89% and poor growth in net sales and operating profit over the last five years. This weak financial performance, combined with a low Debtors Turnover Ratio and flat results in recent quarters, contributes to the stock's declining price.<BR><BR>Despite some positive factors, such as a very attractive valuation and rising investor participation, the overall sentiment remains negative due to the stock's consistent underperformance relative to the market and its peers.

Which are the latest news on Desh Rakshak?